TORRENT PHARMACEUTICALS
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- -
- Established
- 1959-01-01
- Employees
- -
- Market Cap
- $13.7B
Clinical Trials
104
Active:0
Completed:86
Trial Phases
5 Phases
Phase 1:72
Phase 2:5
Phase 3:11
+2 more phases
Drug Approvals
57
FDA:57
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
Clinical Trials
Distribution across different clinical trial phases (98 trials with phase data)• Click on a phase to view related trials
Phase 1
72 (73.5%)Phase 3
11 (11.2%)Not Applicable
6 (6.1%)Phase 2
5 (5.1%)Phase 4
3 (3.1%)phase_1_2
1 (1.0%)Efficacy and Safety of TRC041266 in Patients With Heart Failure, LVEF ≥40%, Diastolic Dysfunction and Type 2 Diabetes Mellitus
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- Torrent Pharmaceuticals Limited
- Registration Number
- NCT04507347
Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris
Phase 3
Completed
- Conditions
- Acne Vulgaris
- Interventions
- Other: Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- Torrent Pharmaceuticals Limited
- Target Recruit Count
- 1150
- Registration Number
- NCT04015375
- Locations
- 🇺🇸
Unison Center for Clinical Trials, Sherman Oaks, California, United States
🇺🇸MOORE Clinical Research, Inc., Brandon, Florida, United States
🇺🇸FXM Clinical Research Miami, Miami, Florida, United States
Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: Forest Pharmaceuticals Inc's Bystolic Tablets
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2018-05-07
- Lead Sponsor
- Torrent Pharmaceuticals Limited
- Target Recruit Count
- 22
- Registration Number
- NCT03517020
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: Forest Pharmaceuticals Inc.'s Bystolic Tablets
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2018-05-07
- Lead Sponsor
- Torrent Pharmaceuticals Limited
- Target Recruit Count
- 30
- Registration Number
- NCT03517033
Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablets Under Fed Conditions
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: Daiichi Sankyo Inc's Benicar Tablets 40 mg
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2017-10-24
- Lead Sponsor
- Torrent Pharmaceuticals Limited
- Target Recruit Count
- 34
- Registration Number
- NCT03319706
- Prev
- 1
- 2
- 3
- 4
- 5
- 15
- Next
News
Biocon Races to Launch First Generic Semaglutide in Canada as Wegovy Patents Expire
Biocon Ltd. is seeking regulatory approval for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting Canada as its first major market entry by 2026.
Indian Pharma Companies to Launch Generic Empagliflozin at 90% Lower Cost
Several Indian pharmaceutical companies are preparing to launch generic versions of Empagliflozin following Boehringer Ingelheim's patent expiry on March 11, potentially transforming diabetes treatment accessibility.